Logo Image
News|Articles|April 9, 2026

GoodRx and Eli Lilly Partner to Expand Access to Foundayo and Zepbound KwikPen

Listen
0:00 / 0:00

Key Takeaways

  • GoodRx–Lilly collaboration operationalizes launch-day, cash-pay access at scale, reflecting manufacturer shifts toward direct-to-patient channels amid variable obesity-drug coverage and payer exclusions.
  • Transparent self-pay pricing is set at $149/month for Foundayo and $299/month for Zepbound KwikPen, leveraging >70,000 pharmacies to create predictable out-of-pocket pathways.
SHOW MORE

Lilly's Foundayo and Zepbound KwikPen are now available on GoodRx for self-pay access.

GoodRx has announced a strategic partnership with Eli Lilly and Company to expand patient access to newly approved GLP-1 therapies through its extensive pharmacy network. The initiative specifically targets the distribution of Foundayo (orforglipron), the novel oral GLP-1 medication that received FDA approval on April 1st, alongside the Zepbound (tirzepatide) KwikPen. The partnership reflects a shift in the pharmaceutical landscape toward direct-to-patient strategies designed to mitigate the impact of inconsistent insurance coverage for obesity treatments. By leveraging a network of more than 70,000 pharmacies, GoodRx says the collaboration delivers transparent self-pay pricing for patients navigating care outside of traditional payer pathways.1

Why Is this Move Significant for Industry Access Trends?

The integration of Foundayo into the GoodRx platform marks a significant industry move toward scaling the consumer-direct access model from the moment of launch. Because insurance coverage for weight loss medications can be variable or unavailable for many Americans, manufacturers are increasingly seeking ways to deliver predictable cash pricing at scale. Eligible self-pay consumers can access Foundayo starting at $149 per month through the GoodRx network, in line with the lowest available discounted cash price at launch.1 GoodRx is also offering self-pay pricing for the Zepbound KwikPen starting at $299 per month, expanding access to both oral and injectable GLP-1 options for adults seeking obesity care outside traditional insurance pathways.1

Wendy Barnes, president and CEO of GoodRx, framed the collaboration as a critical evolution in how new therapies reach patients. "As new GLP-1 therapies continue to expand, including oral options like Foundayo, it is critical that access evolves alongside innovation," Barnes said.1 "By pairing transparent cash pricing with nationwide pharmacy access and integrated care, we are helping ensure more people understand their options and more easily start treatment."1 Laura Steele, group vice president of U.S. Cardiometabolic Health at Eli Lilly, echoed that sentiment, noting the company's commitment to reaching patients through channels that meet them where they are in their treatment journey.1

Is Foundayo Available on TrumpRx?

Beyond the private sector collaboration, Foundayo has also been integrated into federal price transparency efforts. The drug recently launched on TrumpRx, the federal pharmaceutical cost comparison platform that debuted in February, with initial doses starting at $149.2 While Foundayo is also available through Lilly's own direct platform, LillyDirect, White House officials have indicated they believe TrumpRx carries a broader reach than individual manufacturer sites — a signal of growing federal interest in multi-channel access strategies for high-demand therapies.2

What Is Foundayo?

Foundayo itself represents a meaningful clinical milestone in the GLP-1 space. As a small molecule, non-peptide oral GLP-1 receptor agonist, the drug is indicated for chronic weight management in adults with obesity or those who are overweight with at least one weight-related comorbidity, such as hypertension or cardiovascular disease.3 Unlike existing peptide-based GLP-1 therapies that often require specific fasting protocols, Foundayo is the first oral option that can be administered at any time of day without restrictions regarding food or water intake — a distinction that could meaningfully lower the practical barrier to starting and staying on therapy.3 Its regulatory approval was accelerated through the FDA's priority voucher program, which reduced the clinical review timeline to just 50 days after initial filing.

Addressing the persistent barriers to obesity care remains a priority in the pharma industry. Fewer than one in ten people who could benefit from a GLP-1 are currently taking one, held back by access challenges, stigma, perceived complexity, or the belief that their condition isn't serious enough for treatment.3 By providing an oral delivery option with transparent pricing across digital platforms like GoodRx and TrumpRx, stakeholders are attempting to lower these hurdles at scale. As the treatment landscape for metabolic health continues to evolve, these multi-channel direct-to-patient strategies represent a fundamental shift in how chronic weight management is delivered to the millions of Americans living with obesity.

References

Related Content